Genflow Biosciences PLC Announces Strategic Leadership Appointment to Support Expansion Goals

On January 19, 2026, Genflow Biosciences PLC made a formal announcement revealing an important change in its board of directors, underlining the company’s ongoing commitment to scientific progress and global growth. This leadership update is designed to reinforce Genflow’s strategic direction and support its mission to develop innovative gene therapies to treat age-related diseases.

Overview of the Directorate Change

Genflow Biosciences PLC (LSE: GENF and OTCQB: GENFF), a biotechnology firm focused on gene therapies, revealed that Mr. Gad Berdugo, MSc Eng., MBA has joined its Board of Directors with immediate effect.

Mr. Berdugo will take on the role of Independent Non-Executive Chairman, a position in which he will provide strategic guidance as the company advances key scientific and corporate initiatives.

This appointment reflects Genflow’s long-term ambition to expand its research and development capabilities and increase its prominence in both European and U.S. markets.

Continuity in Governance

In addition to the leadership change, Genflow also confirmed that Mrs. Tamara Joseph will continue serving as a Director. Her ongoing participation ensures governance continuity and maintains the strength of the company’s board.

Background and Expertise of the New Chairman

Mr. Gad Berdugo brings more than 30 years of international leadership experience across business development, capital markets, and biotechnology sector strategy. His professional journey includes senior roles with both established and emerging life sciences companies.

Prior to joining Genflow, Mr. Berdugo held several notable positions, including:

• Managing Partner at Explorium Capital LLC — a U.S.-based strategic and financial advisory firm specializing in biotechnology.
• Co-Founder & CEO of EpiVax Oncology.
• Vice-Chairman of the Board for Evexta Bio.
• Chief Business Officer at Editas Medicine, a NASDAQ-listed genome editing company.
• Chief Business Officer at Nutcracker Therapeutics, a biotech firm focused on innovative therapeutics.

Earlier in his career, Mr. Berdugo built his expertise at major global healthcare companies including Abbott Laboratories and Baxter. He also served as Life Sciences Sector Leader at Lazard Asset Management, where he focused on mergers, acquisitions and strategic financing assignments within the life sciences industry.

His deep technical knowledge spans RNA-based therapeutics, lipid nanoparticle delivery systems (LNP), drug development, and manufacturing. This expertise is expected to complement Genflow’s evolving scientific platform and future research directions.

Role and Vision as Chairman

Mr. Berdugo’s role as Independent Non-Executive Chairman places him at the forefront of Genflow’s corporate strategy and global growth efforts. Although he currently does not own shares in the company, his extensive experience in forming strategic partnerships and securing investment capital is anticipated to benefit Genflow’s development over the coming years.

In his comments, Mr. Berdugo highlighted his enthusiasm for joining Genflow during a pivotal phase of its growth, emphasizing key data readouts expected in 2026, a broadened strategic focus, and strengthened intellectual property. He also noted his eagerness to work alongside Genflow’s board and executive team to maximize impact for both patients and shareholders.

Genflow CEO’s Perspective

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, welcomed Mr. Berdugo’s appointment, underlining how his strategic and operational insights will support the company’s expanding research programs. Dr. Leire also praised Mrs. Tamara Joseph for her continued leadership and legal governance contributions.

According to Dr. Leire, the strengthened board composition will play a key role in accelerating Genflow’s development pipeline, extending international engagement, and deepening scientific collaborations as the firm moves toward significant milestones in the near future.

About Genflow Biosciences

Founded in 2020, Genflow Biosciences PLC is a publicly traded biotechnology company headquartered in the United Kingdom, with research facilities in Belgium. The company’s primary focus is the development of novel gene therapies aimed at decelerating the biological aging process and treating age-associated diseases.

Genflow’s lead experimental therapy, GF-1002, utilizes a centenarian variant of the SIRT6 gene, which has demonstrated promising results in pre-clinical studies. As part of its R&D strategy, the company also initiated a 12-month proof-of-concept clinical trial in aged dogs to evaluate the therapy’s impact.

Future clinical investigations planned by Genflow include trials exploring the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a prevalent chronic liver disease for which there are currently no effective treatments.

Strategic Implications and Market Outlook

The appointment of an experienced industry leader such as Mr. Berdugo signals Genflow’s intent to strengthen its position in the competitive biotechnology landscape. His specialized knowledge in RNA technologies and strategic partnerships may help position Genflow to attract more investment and expedite the progression of its development pipeline.

As the company prepares for key data releases and continued scientific validations in 2026, this leadership change may be viewed by stakeholders as a positive step toward achieving long-term growth and operational success.

Conclusion

Genflow Biosciences PLC’s announcement of Mr. Gad Berdugo as its new Independent Non-Executive Chairman represents a strategic evolution in the company’s leadership structure. With a board composed of experienced directors and a clearly defined vision for its research endeavors, Genflow is positioning itself for continued progress in gene therapy innovation and global market expansion.

#GenflowBiosciences #BiotechLeadership #GeneTherapy #LifeSciencesInnovation #SlimScan #GrowthStocks #CANSLIM